Markers of endothelial dysfunction in attack-like schizophrenia

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 105, Issue 3, 2005, Pages 43-46

  Shcherbakova, I V ^a   Kaleda, V G ^a   Barkhatova, A N ^a   Klyushnik, T P ^a  

^a NONE

Author keywords

Attack like schizophrenia; Blood brain barrier; C reactive protein; Leukocyte elastase; Von Willebrand factor

Indexed keywords

C REACTIVE PROTEIN; LEUKOCYTE ELASTASE; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BLOOD BRAIN BARRIER; COMPARATIVE STUDY; HUMAN; MALE; PATHOPHYSIOLOGY; SCHIZOPHRENIA; STATISTICAL ANALYSIS; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; BLOOD-BRAIN BARRIER; C-REACTIVE PROTEIN; DATA INTERPRETATION, STATISTICAL; ENDOTHELIUM, VASCULAR; HUMANS; LEUKOCYTE ELASTASE; MALE; SCHIZOPHRENIA; VON WILLEBRAND FACTOR;

EID: 17844410385     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Aznar-Salatti J., Bastida E., Buchanan M.R. et al. Differential localization of von Willebrand factor, fibronectin and I3-HODE in human endothelial cell culture. Histochemistry 1990; 93: 5: 507-511.
2. Blann A.D., Seigneur M., Adams R.A., McCollum C.N. Neutrophil elastase, von Willebrand factor, soluble thrombomodulin and percutaneus oxygen in peripheral atherosclerosis. Eur J Vasc Endovasc Surg 1996; 12: 2: 218-222.
3. Boneu B., Abbal M., Plante J., Bierme R. Factor-VIII complex and endothelial damage. Lancet 1975; 1: 7922: 1430.
4. Bonnefoy A., Legrand C. Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospodin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase. Thromb Res 2000; 98: 4: 323-332.
5. Chignard M., Balloy V., Renesto P. Leukocyte elastase-mediated release of von Willebrand factor from cultured endothelial cells. Eur Respir J 1993; 6: 6: 791-796.
6. Falanga A., Marchetti M., Evangelista V. et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999; 93: 8: 2506-2514.
7. Felmeden D.C., Spencer C.G., Chung N.A. et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOTJ). Am J Cardiol 2003; 92: 4: 400-405.
8. Hattori Y., Matsumura M., Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003; 58: 1: 186-195.
9. Jacob M.P., Badier-Commander C., Fontaine V. et al. Extracellular matrix remodeling in the vascular wall. Pathol Biol (Paris) 2001; 49: 4: 326-332.
10. Kessler L., Wiesel M.L., Attali P. et al. Von Willebrand factor in diabetic angiopathy. Diabetes Metab 1998; 24: 4: 327-336.
11. Kirch D.G. Infection and autoimmunity as etiologic factor in schizophrenia: a review and reappraisal. Schizophr Bull 1993; 19: 2: 355-370.
12. Kushner J., Gewurz H., Benson M. C-reactive protein and acute-phase response. J Lab Clin Med 1981; 97: 6: 739-749.
13. Kozuka K., Kohriyama T., Nomura E. et al. Endothelial markers and adhesion molecules in acute ischemic stroke - sequential change and differences in stroke subtype. Atherosclerosis 2002; 161: 1: 161-168.
14. Manolov D.E., Koenig W., Hombach V., Torzewski J. C-reactive protein and atherosclerosis. Is there a causal link? Histol Histopathol 2003; 18: 4: 1189-1193.
15. McGirt M.J., Lynch J.R., Blessing R. et al. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 2002; 51: 5: 1128-1134.
16. Muller N., Riedel M., Gruber R. et al. The immune system and schizophrenia. An integrative view. Ann NY Acad Sci 2000; 917: 456-467.
17. Nagy Z., Kolev K., Csonka E. et al. Perturbation of the integrity of the blood-brain barrier by fibrinolytic enzymes. Blood Coagul Fibrinolysis 1998; 9: 6: 471-478.
18. Nakatani K., Takeshita S., Tsujimoto H. et al. Inhibitory effect of serine protease inhibitors on neutrophil-mediated endothelial cell injury. J Leukoc Biol 2001; 69: 2: 241-247.
19. Ruddock V., Meade T.W. Factor VII activity and ischaemic heart disease: Fatal and non-fatal events. Q J Med 1994; 87: 403-406.
20. Sadler J.E. Von Willebrand factor. J Biol Chem 1991; 266: 22777-22784.
21. Schalkwijk C.G., Poland D.C., van Dijk W. et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 3: 351-357.
22. Shcherbakova I., Neshkova E., Dotsenko V. et al. The possible role of plasma kallikrein-kinin system and leukocyte elastase in pathogenesis of schizophrenia. Immunopharmacology 1999; 43: 273-279.
23. Tohgi H., Takahashi H., Tamara K. et al. Ischemic stroke among inpatients with preceding inflammatory response. Thromb Res 2001; 104: 5: 375-377.
24. Torzewski J., Torzewski M., Bowyer D.E. et al. C-reactive protein frequently colocolizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18: 9: 1386-1392.
25. Torzewski M., Rist C., Mortensen R.F. et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Atheroscler Thromb Vasc Biol 2000; 20: 2094-2099.
26. Verma S., Li S.H., Badiwala M.V. et al. Endothelin antagonism and interleukin-6 attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105: 16: 1890-1896.
27. Wang C.H., Li S.H., Weisel R.D. et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 13: 1783-1790.
28. Comment in: Circulation 2003; 108: 15: 113.
29. Westlin W.F., Gimbrone M.A. Neutrophil-mediated damage to human vascular endothelium. Am J Pathol 1993; 142: 117-128.
30. Wong C.T., Tsoi W.F., Saha N. Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res 1996; 22: 2: 165-171.
31. Zorrilla E.P., Cannon T.D., Kessler J., Cur R.E. Leukocyte differentials predict short-term clinical outcome following antipsychotic treatment in schizophrenia. Biol Psychiat 1998; 43: 887-896.